Find Novel Dermatology Drugs in Clinical Development

Lead Product(s): Cannabinoid based products

Therapeutic Area: Dermatology

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

The cannabis research license by Health Canada allows the Crescita to possess cannabis for the purpose of research and development.

Lead Product(s): TFC-1067

Therapeutic Area: Dermatology

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

TFC-1067 demonstrated very good skin compatibility and does not show a sensitizing effect.

Lead Product(s): Bispecific antibody

Therapeutic Area: Dermatology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Almirall, S.A

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 09, 2020

Details:

With this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatology diseases including atopic dermatitis.

Lead Product(s): Bispecific antibody

Therapeutic Area: Dermatology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Almirall, S.A

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 09, 2020

Details:

Almirall will secure the rights to develop and commercialize the antibody for worldwide use. This agreement will strengthen Almirall's early-stage research portfolio.